search
Back to results

Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study (CASCADE)

Primary Purpose

Lung Cancer Screening

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Low-dose computed tomography of the chest
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Lung Cancer Screening focused on measuring lung neoplasms, multidetector computed tomography, early detection of cancer, artificial intelligence, lung cancer screening

Eligibility Criteria

50 Years - 74 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Women aged from 50 to 74 years
  • who had smoked at least 20 pack years and quit less than 15 years ago
  • Had given their consent and accepted the need for a 2-year follow-up
  • Affiliated to the social security system

Exclusion Criteria

  • Presence of clinical symptoms suggesting malignancy (weight loss, hemoptysis) or ongoing infection (cough with fever)
  • Evolving cancer
  • History of lung cancer
  • A 2-year follow-up not possible
  • Chest CT scan performed within 2 years prior to inclusion

Sites / Locations

  • Hôtel-DieuRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Procedure

Arm Description

Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules

Outcomes

Primary Outcome Measures

Performance of trained radiologists for lung cancer screening
Sensitivity, specificity, predictive values compared to double reading by experts

Secondary Outcome Measures

Effectiveness of screening
Proportion of participants with a positive screening test and proportion of confirmed diagnosis of cancer
Analysis of the diagnostic performance of the reading without detection software, in order to assess its incremental value
Sensitivity, specificity, predictive values and likelihood ratios of the initial reading compared to the expert readings, using histological diagnosis as gold standard for positive screens and stability at 2 years for negative screens
Analysis of the performance of a reading by detection software alone
Sensitivity, specificity, predictive values and likelihood ratios of artificial intelligence alone
Analysis of the concordances of the different readings
Kappa concordance coefficient between the different readings
Adherence to screening
Number of participants related to the number of eligible women, having completed all the required scans (3 to 6), speed of inclusion in the study
Analysis of the impact of screening on smoking cessation
Smoking cessation rate at the end of the study
Psychological impact of screening
HADS (Hospital Anxiety and Depression Scale) questionnaire at each scan, Cancer worry scale, Satisfaction with Decision scale at inclusion and end of study, all translated into French
Number of co-morbidities (COPD, coronary artery disease) detected
Number of participants related to the number of women included in the study for whom treatment is initiated (bronchodilators/ statins or revascularization/ osteoporosis treatment)
Evaluation of costs induced by screening
Cost measures: total cost of screening, average cost per woman, average cost per woman screened
Prevalence of osteoporosis by opportunistic screening
Presence of at least one thoracic vertebral fracture and measurement of trabecular attenuation of the T8 vertebral body

Full Information

First Posted
January 4, 2022
Last Updated
September 26, 2022
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Ministère de la Santé et des Solidarités, National Cancer Institute, France
search

1. Study Identification

Unique Protocol Identification Number
NCT05195385
Brief Title
Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study
Acronym
CASCADE
Official Title
Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 8, 2022 (Actual)
Primary Completion Date
April 8, 2024 (Anticipated)
Study Completion Date
October 8, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Ministère de la Santé et des Solidarités, National Cancer Institute, France

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether reading of low-dose thoracic CT scans can be done by a single general radiologist who has been trained to lung cancer screening, and will evaluate the performance in comparison with double reading by experts. The study will enroll women between 50 and 74 years old, at risk for lung cancer due to their smoking history.
Detailed Description
Lung cancer is the leading cause of cancer death, worldwide. Several randomized studies have demonstrated that annual or biennial low-dose CT screening reduces lung cancer mortality. However, these studies involved expert chest radiologists, with double reading being performed in most studies. Furthermore, none of the published studies have evaluated the role of artificial intelligence to serve as second of concurrent reader. Women with at least 25 pack-year smoking history who quitted smoking less than 15 years ago will be enrolled to have baseline, 1-year and 2-year low-dose CT of the chest. The CT scans will be read on site by a general radiologist trained to lung cancer screening according to the European lung cancer screening certification program, first without then with the aid of an artificial algorithm trained to lung nodule detection (Veye Chest, Aidence). All CT scans will also be read by 2 chest experts, who will resolve their disagreement by a consensus reading if necessary. Patient management will rely on the double reading by expert. The criteria for positive screen result are as follows: solid nodule > 500 mm3 (10 mm) or growing (30% volume increase), part-solid nodule with > 8 mm solid component or new or growing, pure ground glass nodule developing a solid portion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer Screening
Keywords
lung neoplasms, multidetector computed tomography, early detection of cancer, artificial intelligence, lung cancer screening

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
2400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Procedure
Arm Type
Other
Arm Description
Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules
Intervention Type
Procedure
Intervention Name(s)
Low-dose computed tomography of the chest
Intervention Description
Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules
Primary Outcome Measure Information:
Title
Performance of trained radiologists for lung cancer screening
Description
Sensitivity, specificity, predictive values compared to double reading by experts
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Effectiveness of screening
Description
Proportion of participants with a positive screening test and proportion of confirmed diagnosis of cancer
Time Frame
2 years
Title
Analysis of the diagnostic performance of the reading without detection software, in order to assess its incremental value
Description
Sensitivity, specificity, predictive values and likelihood ratios of the initial reading compared to the expert readings, using histological diagnosis as gold standard for positive screens and stability at 2 years for negative screens
Time Frame
2 years
Title
Analysis of the performance of a reading by detection software alone
Description
Sensitivity, specificity, predictive values and likelihood ratios of artificial intelligence alone
Time Frame
2 years
Title
Analysis of the concordances of the different readings
Description
Kappa concordance coefficient between the different readings
Time Frame
2 years
Title
Adherence to screening
Description
Number of participants related to the number of eligible women, having completed all the required scans (3 to 6), speed of inclusion in the study
Time Frame
2 years
Title
Analysis of the impact of screening on smoking cessation
Description
Smoking cessation rate at the end of the study
Time Frame
2 years
Title
Psychological impact of screening
Description
HADS (Hospital Anxiety and Depression Scale) questionnaire at each scan, Cancer worry scale, Satisfaction with Decision scale at inclusion and end of study, all translated into French
Time Frame
2 years
Title
Number of co-morbidities (COPD, coronary artery disease) detected
Description
Number of participants related to the number of women included in the study for whom treatment is initiated (bronchodilators/ statins or revascularization/ osteoporosis treatment)
Time Frame
2 years
Title
Evaluation of costs induced by screening
Description
Cost measures: total cost of screening, average cost per woman, average cost per woman screened
Time Frame
2 years
Title
Prevalence of osteoporosis by opportunistic screening
Description
Presence of at least one thoracic vertebral fracture and measurement of trabecular attenuation of the T8 vertebral body
Time Frame
2 years

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women aged from 50 to 74 years who had smoked at least 20 pack years and quit less than 15 years ago Had given their consent and accepted the need for a 2-year follow-up Affiliated to the social security system Exclusion Criteria Presence of clinical symptoms suggesting malignancy (weight loss, hemoptysis) or ongoing infection (cough with fever) Evolving cancer History of lung cancer A 2-year follow-up not possible Chest CT scan performed within 2 years prior to inclusion
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marie-Pierre REVEL, PhD
Phone
+33 1 42 34 79 10
Email
marie-pierre.revel@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Adèle BELLINO, MS
Phone
+33 1 58 41 11 95
Email
adele.bellino@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marie-Pierre REVEL, PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Marie WISLEZ, PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôtel-Dieu
City
Paris
ZIP/Postal Code
75004
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marie-Pierre REVEL, PhD
Phone
+33 1 42 34 79 10
Email
marie-pierre.revel@aphp.fr
First Name & Middle Initial & Last Name & Degree
Marie WISLEZ, PhD
Phone
+33 1 58 41 19 06
Email
marie.wislez@aphp.fr

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study

We'll reach out to this number within 24 hrs